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Dear Editor,
I read with great interest the paper by Taheri et al. pub-
lished  in  (1)  Hepatitis  Monthly  (Number  31,  February 
2011). The results of this follow-up study are hopeful of 
hepatitis-B vaccine efficacy in patients who lost HBsAg 
and did not seroconvert to anti-HBs with no detectable 
HBV DNA. However, the editorial in the same issue, as 
well as Taheri et al. themselves, noted some important 
limitations to this study (2). According to the findings 
of a meta-analysis by Poorolajal et al. (3), the protection 
provided by the HBV vaccine is dependent on immune 
memory rather than circulating anti-HBs titer. Therefore, 
it would be worthwhile to observe the anamnestic im-
mune response to HBsAg in such patients. Furthermore, 
such  an  investigation  should  include  observations  of 
spontaneous developing anamnestic immune response. 
The authors prefer an artus HBV RG PCR kit for HBV DNA 
detection  but  not  for  quantification.  Because  of  the 
lower analytic sensitivity (10.22 IU/ml), the artus HBV QS-
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  Implication  for  health  policy/practice/research/medical 
education:
This letter to editor has been written to discussed of article pub-
lished in Hepat Mon. 2011;11(2). The researcher and clinicians 
should be remembered of false HBsAg negativitiy in the man-
agement of occult hepatitis B patients.
RGQ kit (QIAGEN GmbH, Hilden Germany) would be an 
incorrect chocie for this study design. Therefore, absent 
of measuring the HBV viral load as stated in the editorial, 
the HBV RG PCR kit does not present any limitations for 
following-up with occult hepatitis B patients. 
In Taheri et al.’s study, some patients with undetectable 
HBV  DNA  require  more  explanation.  Specifically,  they 
test negative for HBsAg but still test positive for HBeAg 
[Study Groups 2 and 3 (4%)]. However, seroconversion to 
anti-HBs in these patients is not clear. Also, the patients 
in Group 1, who tested negative for HBsAg but had detect-
able amounts of HBV DNA, should be analyzed for typical 
HBsAg escape mutation. The literature has discussed that 
some emergent mutations in the S gene region of HBV 
(naturally occuring or dependet to oral antiviral using) 
may cause diagnostic problems for some of the typical 
HBsAg  escape  mutations  and  may  not  be  detected  in 
HBsAg assays (4). Patients who have or are infected with 
diagnostic escape HBsAg mutation cannot be considered 
as lost HBsAg. Finally, despite a low protection rate (5) of 
anti-HBs antibody level (68 ± 32.66) in a small number of 
patients, the findings of Taheri et al.’s study establishes 
that a new approach to managing occult hepatitis B in-
fection may be to use nucleos(t)ide analogue treatments 
on patients who test negative for HBsAg.Hepat Mon. 2011;11(4):299-300
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